Mona Basha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mona Basha has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed Alaa Kassem
Pharmaceutical Technology Department, National Research Centre, El- Buhouth St., Dokki, Cairo 12622, Egypt
4 shared publications - Hadeer Ahmed El-Hashemy
Pharmaceutical Technology Department, National Research Centre, Cairo, Egypt
4 shared publications - Sally A. El Awdan
Department of Pharmacology, Medical Research and Clinical studies Institute, National Research Centre (ID: 60014618)
4 shared publications - Sameh Hosam Abd El-Alim
Pharmaceutical Technology Department, National Research Centre, Cairo, Egypt
4 shared publications - Ghada E. A. Awad
National Research Centre
3 shared publications - Rabab Kamel
Pharmaceutical Technology Department, National Research Centre, Cairo, Egypt
3 shared publications
Latest Publications
- Open Access
- 6 December 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (12) , 2738
Cellulosic Textiles—An Appealing Trend for Different Pharmaceutical Applications
Cellulose, the most abundant biopolymer in nature, is derived from various sources. The production of pharmaceutical textiles based on cellulose represents a growing sector. In medicated textiles, textile and pharmaceutical sciences are integrated to develop new healthcare approaches aiming to improve patient compliance. Through the possibility of cellulose functionalization, pharmaceutical textiles can broaden the applications of cellulose in the biomedical field. This narrative review aims to illustrate both the methods of extraction and preparation of cellulose fibers, with a particular focus on nanocellulose, and diverse pharmaceutical applications like tissue restoration and antimicrobial, antiviral, and wound healing applications. Additionally, the merging between fabricated cellulosic textiles with drugs, metal nanoparticles, and plant-derived and synthetic materials are also illustrated. Moreover, new emerging technologies and the use of smart medicated textiles (3D and 4D cellulosic textiles) are not far from those within the review scope. In each section, the review outlines some of the limitations in the use of cellulose textiles, indicating scientific research that provides significant contributions to overcome them. This review also points out the faced challenges and possible solutions in a trial to present an overview on all issues related to the use of cellulose for the production of pharmaceutical textiles.
- 6 December 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (12) , 2738
Open AccessCellulosic Textiles—An Appealing Trend for Different Pharmaceutical Applications
Cellulose, the most abundant biopolymer in nature, is derived from various sources. The production of pharmaceutical textiles based on cellulose represents a growing sector. In medicated textiles, textile and pharmaceutical sciences are integrated to develop new healthcare approaches aiming to improve patient compliance. Through the possibility of cellulose functionalization, pharmaceutical textiles can broaden the applications of cellulose in the biomedical field. This narrative review aims to illustrate both the methods of extraction and preparation of cellulose fibers, with a particular focus on nanocellulose, and diverse pharmaceutical applications like tissue restoration and antimicrobial, antiviral, and wound healing applications. Additionally, the merging between fabricated cellulosic textiles with drugs, metal nanoparticles, and plant-derived and synthetic materials are also illustrated. Moreover, new emerging technologies and the use of smart medicated textiles (3D and 4D cellulosic textiles) are not far from those within the review scope. In each section, the review outlines some of the limitations in the use of cellulose textiles, indicating scientific research that provides significant contributions to overcome them. This review also points out the faced challenges and possible solutions in a trial to present an overview on all issues related to the use of cellulose for the production of pharmaceutical textiles.
- 22 May 2020
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 16 (2) , 384-390
Bioanalytical Comparison of Transdermal Delivery of Tizanidine from Different Nanovesicular Carriers
- 22 May 2020
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 16 (2) , 384-390
Bioanalytical Comparison of Transdermal Delivery of Tizanidine from Different Nanovesicular Carriers
- 1 February 2019
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 49, 365-374
A promising nystatin nanocapsular hydrogel as an antifungal polymeric carrier for the treatment of topical candidiasis
- 1 February 2019
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 49, 365-374
A promising nystatin nanocapsular hydrogel as an antifungal polymeric carrier for the treatment of topical candidiasis
- 11 September 2018
- Published by Taylor & Francis in Journal of Liposome Research
- Vol. 29 (2) , 171-182
Evaluation of bilosomes as nanocarriers for transdermal delivery of tizanidine hydrochloride:in vitroandex vivooptimization
Bilosomes were developed in order to investigate their efficacy as nanocarriers for transdermal delivery of Tizanidine HCl (TZN), a skeletal muscle relaxant with low oral bioavailability. Full factorial experimental design consisting of 27 combinations was generated to study the effects of surfactant type, surfactant-to-cholesterol ratio and the amount of bile salt on the entrapment efficiency (EE), the vesicle size (VS) and in vitro dissolution of the TZN-loaded bilosomes. The permeation through the stratum cornea was optimized with the vertical diffusion assembly using excised rat skin. The permeation parameters of the selected bilosomes were compared to the unformulated drug and it was shown that TZN-B24 exhibited the highest enhancement ratio (ER = 8.8).The optimal formula (TZN-B24) consisting of span 60 in a ratio with cholesterol of 1:1 and 20 mg of bile salt was obtained by employing the desirability function of Design-Expert® software. The mathematical model used for the optimization was validated by comparing the predicted values of the EE (82.3%) and the VS (165.8 nm) with the experimental values of EE = 84.42% and of VS = 161.95 nm. TZN-B24 displayed high zeta potential which contributed to its good stability. It was evident from the results of this study that incorporating TZN in bilosomes improved significantly its permeation through the skin barrier and thus bilosomes can offer a potential nanoplatform using the transdermal route to improve the bioavailability of the drug.
- 11 September 2018
- Published by Taylor & Francis in Journal of Liposome Research
- Vol. 29 (2) , 171-182
Evaluation of bilosomes as nanocarriers for transdermal delivery of tizanidine hydrochloride:in vitroandex vivooptimization
Bilosomes were developed in order to investigate their efficacy as nanocarriers for transdermal delivery of Tizanidine HCl (TZN), a skeletal muscle relaxant with low oral bioavailability. Full factorial experimental design consisting of 27 combinations was generated to study the effects of surfactant type, surfactant-to-cholesterol ratio and the amount of bile salt on the entrapment efficiency (EE), the vesicle size (VS) and in vitro dissolution of the TZN-loaded bilosomes. The permeation through the stratum cornea was optimized with the vertical diffusion assembly using excised rat skin. The permeation parameters of the selected bilosomes were compared to the unformulated drug and it was shown that TZN-B24 exhibited the highest enhancement ratio (ER = 8.8).The optimal formula (TZN-B24) consisting of span 60 in a ratio with cholesterol of 1:1 and 20 mg of bile salt was obtained by employing the desirability function of Design-Expert® software. The mathematical model used for the optimization was validated by comparing the predicted values of the EE (82.3%) and the VS (165.8 nm) with the experimental values of EE = 84.42% and of VS = 161.95 nm. TZN-B24 displayed high zeta potential which contributed to its good stability. It was evident from the results of this study that incorporating TZN in bilosomes improved significantly its permeation through the skin barrier and thus bilosomes can offer a potential nanoplatform using the transdermal route to improve the bioavailability of the drug.
- 1 June 2018
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 544 (1) , 129-140
A potential antibacterial wound dressing of cefadroxil chitosan nanoparticles in situ gel: Fabrication, in vitro optimization and in vivo evaluation
- 1 June 2018
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 544 (1) , 129-140
A potential antibacterial wound dressing of cefadroxil chitosan nanoparticles in situ gel: Fabrication, in vitro optimization and in vivo evaluation
- 1 May 2018
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 111, 604-613
Chitosan nanoparticles/cellulose nanocrystals nanocomposites as a carrier system for the controlled release of repaglinide
- 1 May 2018
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 111, 604-613
Chitosan nanoparticles/cellulose nanocrystals nanocomposites as a carrier system for the controlled release of repaglinide
- 1 January 2018
- Published by Bentham Science Publishers Ltd. in Current Drug Delivery
- Vol. 15 (4) , 497-509
Nanotechnology as a Promising Strategy for Anticancer Drug Delivery
Background: Cancer was and still a very stressful and urgent disease condition representing a leading cause of death in developed as well as developing countries. Although, much research work in both medical and pharmaceutical fields has evolved in the past few years in addition to some promising clinical trials and few market products, cancer becomes much wilder, threatening and getting more lives. Most approaches have focused on the synthesis of new active ingredients or chemical modification of available ones, formulating them in suitable dosage forms aiming for targeted and effective drug delivery with minimal side effects. Method: Recently, application of nanotechnology through formulation of nanocarriers has acquired much more attention in treating different types of cancer tumors. Being explored in cancer therapy, nanocarriers have shown a promising capability to enhance intracellular uptake of active agents, promoting their accumulation in the tumor mass in addition to the reduction of the cellular toxicity compared to conventional chemotherapeutics. Results: In view of the above findings, this review discusses recent advances in nanotechnology-based carriers for cancer drug delivery, providing detailed description of different nanocarriers from historical perspective since the first developed carrier up to the new strategies adopted to formulate novel multifunctional targeted nanocarriers for cancer therapy. Conclusion: The findings of this review illustrate the potential of nanotechnology-based carriers as an emerging technology for more satisfying and selective cancer therapy.
- 1 January 2018
- Published by Bentham Science Publishers Ltd. in Current Drug Delivery
- Vol. 15 (4) , 497-509
Nanotechnology as a Promising Strategy for Anticancer Drug Delivery
Background: Cancer was and still a very stressful and urgent disease condition representing a leading cause of death in developed as well as developing countries. Although, much research work in both medical and pharmaceutical fields has evolved in the past few years in addition to some promising clinical trials and few market products, cancer becomes much wilder, threatening and getting more lives. Most approaches have focused on the synthesis of new active ingredients or chemical modification of available ones, formulating them in suitable dosage forms aiming for targeted and effective drug delivery with minimal side effects. Method: Recently, application of nanotechnology through formulation of nanocarriers has acquired much more attention in treating different types of cancer tumors. Being explored in cancer therapy, nanocarriers have shown a promising capability to enhance intracellular uptake of active agents, promoting their accumulation in the tumor mass in addition to the reduction of the cellular toxicity compared to conventional chemotherapeutics. Results: In view of the above findings, this review discusses recent advances in nanotechnology-based carriers for cancer drug delivery, providing detailed description of different nanocarriers from historical perspective since the first developed carrier up to the new strategies adopted to formulate novel multifunctional targeted nanocarriers for cancer therapy. Conclusion: The findings of this review illustrate the potential of nanotechnology-based carriers as an emerging technology for more satisfying and selective cancer therapy.
- 1 October 2017
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 532 (1) , 478-490
Reconstitutable spray dried ultra-fine dispersion as a robust platform for effective oral delivery of an antihyperlipidemic drug
- 1 October 2017
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 532 (1) , 478-490
Reconstitutable spray dried ultra-fine dispersion as a robust platform for effective oral delivery of an antihyperlipidemic drug